Global Insulin Delivery Devices Market – Industry Trends - Forecast to 2026

  • Drug Delivery Devices
  • Upcoming Reports
  • May 2019
  • Global
  • 350 Pages
  • No of Tables: 50
  • No of Figures: 250

Global Insulin Delivery Devices Market By Product Type (Insulin Syringes, Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes, Insulin Injectors), End User (Homecare, Hospitals, Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Market Analysis: Global Insulin Delivery Devices Market

Global Insulin Delivery Devices Market is expected to rise from its initial estimated value of USD 10.7 billion in 2018 to an estimated value of USD 21.7 billion by 2026, registering a CAGR of 9.2% in the forecast period of 2019-2026. The increase in diabetic population drives the rise in the market.

Market Definition: Global Insulin Delivery Devices Market

Insulin is considered to be an important part of the treatment plan for all people who have Type 1 and Type 2 diabetes Insulin delivery device is injected into the fatty tissues under the skin with the help of syringes, insulin pens, insulin pumps and jet injectors. It’s important to select the best device with help of diabetes care team; every device has different functionality. Increasing number of diabetic patient is the growing factor of this industry.

Market Drivers

  • Increasing diabetic population is acting as a restraint for the market.
  • More of technological advancement
  • Favorable reimbursement scenario
  • Rising awareness about the product

Market Restraints

  • High cost of advanced devices.
  • Complicated software’s.
  • Unskilled professionals for handling advanced devices.

Segmentation: Global Insulin Delivery Devices Market

By Product

  • Pens
  • Reusable Insulin Pens
  • Disposable Insulin Pens
  • Insulin
  • External/Tethered Pumps
  • Patch Pumps
  • Pumps

    • Tubed pumps
    • Tubeless pumps

  • Pen Needles
  • Standard Pen Needles
  • Safety Pen Needles
  • Insulin Syringes

By End- User

  • Hospitalsl
  • Clinic
  • Home Care

By Geography

  • North America

    • US.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Argentina
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific

  • Middle East & Africa

    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In February 2019, FDA provides approvals for two new devices which are designed to improve automated insulin delivery. The Tandem Diabetes Care introduced new product Slim X2 insulin pump which is first interoperable pump approved for children and adults.
  • In February 2019, MIT-led research team announces the launch of newly developed drug capsule which can replace injection required for type 1 diabetes. The capsule is made of small needle from compressed insulin.

Competitive Analysis: Global Insulin Delivery Devices Market

Global insulin delivery devices market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of insulin delivery devices market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Insulin Delivery Devices Market

Few of the major competitors currently working in the global insulin delivery devices market are BD, Medtronic, Ypsomed, Novo Nordisk India Pvt Ltd, Beta Bionics, Owen Mumford Ltd., Sanofi, Tandem Diabetes Care, Inc., Copernicus, Dance Biopharm Holdings Inc., Insulet Corporation, Biocon, Eli Lilly, West Pharmaceutical Services, Inc., F. Hoffmann-La Roche Ltd, Debiotech S.A, InsuJet, SHL Group, SOOIL Developments Co., Ltd and Company and few among others

Research Methodology: Global Insulin Delivery Devices Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global insulin delivery devices market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

SKU-

TABLE OF CONTENTS GLOBAL INSULIN DELIVERY DEVICES MARKET

1. INTRODUCTION

1.1 OVERVIEW OF THE GLOBAL INSULIN DELIVERY DEVICES MARKET 1.2 CURRENCY AND PRICING 1.3 LIMITATION 1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL INSULIN DELIVERY DEVICES MARKET

2.2.1 VENDOR POSITIONING GRID 2.2.2 TECHNOLOGY LIFE LINE CURVE 2.2.3 MARKET TIME LINE 2.2.4 MARKET GUIDE 2.2.5 COMPANY POSITIONING GRID 2.2.6 COMAPANY MARKET SHARE ANALYSIS 2.2.7 MULTIVARIATE MODELLING 2.2.8 STANDARDS OF MEASUREMENT 2.2.9 TOP TO BOTTOM ANALYSIS 2.2.10 VENDOR SHARE ANALYSIS 2.2.11 EPIDEMIOLOGY MODELLING 2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS 2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL INSULIN DELIVERY DEVICES MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING PREVALENCE OF DIABETES 3.1.2 TECHNOLOGICAL ADVANCEMENTS 3.1.3 HIGH ADOPTION OF INSULIN PENS 3.1.4 RISING GOVERNMENT INITIATIVES 3.1.5 FAVORABLE REIMBURSEMENT ENVIRONMENT 3.1.6 RISING AWARENESS ABOUT INSULIN DELIVERY DEVICES

3.2 RESTRAINTS

3.2.1 POOR REIMBURSEMENT IN DEVELOPING COUNTRIES 3.2.2 NEEDLE PHOBIA OF THE PEN NEEDLES AND SYRINGES 3.2.3 ALTERNATIVE DRUG DELIVERY METHOD

3.3 OPPORTUNITIES

3.3.1 INCREASING RESEARCH AND DEVELOPMENT 3.3.2 INCREASING DIABETES-RELATED HEALTH EXPENDITURE

3.4 CHALLENGES

3.4.1 SHORTAGE OF ENDOCRINOLOGIST 3.4.2 PRODUCT RECALL

4 EXECUTIVE SUMMARY 5 PREMIUM INSIGHTS 6 GLOBAL INSULIN DELIVERY DEVICES MARKET, BY TYPE

6.1 OVERVIEW

6.2 INSULIN PENS

6.2.1 REUSABLE INSULIN PENS 6.2.2 DISPOSABLE INSULIN PENS

6.3 INSULIN PUMPS

6.3.1 EXTERNAL/TETHERED PUMPS 6.3.2 PATCH PUMPS

6.4 PEN NEEDLES

6.4.1 STANDARD PEN NEEDLES 6.4.2 SAFETY PEN NEEDLES

6.5 INSULIN SYRINGES

6.5.1 1-UNIT DOSE 6.5.2 2-UNIT DOSE

6.6 INHALABLE INSULIN

6.7 WEARABLE INSULIN DELIVERY DEVICES

6.8 OTHER INSULIN DELIVERY DEVICES

7 GLOBAL INSULIN DELIVERY DEVICES MARKET, BY THERAPY

7.1 OVERVIEW 7.2 SHORT-ACTING INSULIN DERIVATIVES 7.3 INTERMEDIATE-ACTING INSULIN DERIVATIVES 7.4 LONG-ACTING INSULIN DERIVATIVES 7.5 RAPID-ACTING INSULIN DERIVATIVES 7.6 PREMIXED INSULIN DERIVATIVES

8 GLOBAL INSULIN DELIVERY DEVICES MARKET, BY END USER

8.1 OVERVIEW 8.2 HOMECARE 8.3 HOSPITALS & CLINICS 8.4 AMBULATORY CARE 8.5 OTHERS

9 GLOBAL INSULIN DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW 9.2 HOSPITAL PHARMACIES 9.3 PHARMACY STORES 9.4 ONLINE PHARMACIES 9.5 OTHERS

10 GLOBAL INSULIN DELIVERY DEVICES MARKET, BY COUNTRY

10.1 COUNTRYWISE INSULIN DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

10.1.1 NORTH AMERICA

10.1.1.1 U.S. 10.1.1.2 CANADA 10.1.1.3 MEXICO

10.1.2 EUROPE

10.1.2.1. GERMANY 10.1.2.2 FRANCE 10.1.2.3 U.K. 10.1.2.4 ITALY 10.1.2.5 SPAIN 10.1.2.6 RUSSIA 10.1.2.7 TURKEY 10.1.2.8 BELGIUM 10.1.2.9 NETHERLANDS 10.1.2.10 SWITZERLAND 10.1.2.11 REST OF EUROPE

10.1.3 ASIA-PACIFIC (APAC)

10.1.3.1 JAPAN 10.1.3.2 CHINA 10.1.3.3 SOUTH KOREA 10.1.3.4 INDIA 10.1.3.5 AUSTRALIA 10.1.3.6 SINGAPORE 10.1.3.7 THAILAND 10.1.3.8 MALAYSIA 10.1.3.9 INDONESIA 10.1.3.10 PHILIPPINES 10.1.3.11 REST OF APAC

10.1.4 SOUTH AMERICA

10.1.4.1 BRAZIL 10.1.4.2 REST OF LATIN AMERICA

10.1.5 MIDDLE EAST AND AFRICA

10.1.5.1 SAUDI ARABIA 10.1.5.2 SOUTH AFRICA 10.1.5.3 REST OF MIDDLE EAST AND AFRICA

10.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

11 GLOBAL INSULIN DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE

11.1. GLOBAL INSULIN DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS 11.2. MERGERS & ACQUISITIONS 11.3. NEW PRODUCT DEVELOPMENT & APPROVALS 11.4. EXPANSIONS 11.5. REGULATORY CHANGES 11.6. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

12 GLOBAL INSULIN DELIVERY DEVICES MARKET, COMPANY PROFILES

12.1 BECTON, DICKINSON AND COMPANY

12.1.1 COMPANY OVERVIEW 12.1.2 FINANCIAL ANALYSIS 12.1.3 PRODUCT MATRIX 12.1.4 RECENT DEVELOPMENTS 12.1.5 DATABRIDGE ANALYSIS

12.2 NOVO NORDISK A/S

12.2.1 COMPANY OVERVIEW 12.2.2 FINANCIAL ANALYSIS 12.2.3 PRODUCT MATRIX 12.2.4 RECENT DEVELOPMENTS 12.2.5 DATABRIDGE ANALYSIS

12.3 MEDTRONIC

12.3.1 COMPANY OVERVIEW 12.3.2 FINANCIAL ANALYSIS 12.3.3 PRODUCT MATRIX 12.3.4 RECENT DEVELOPMENTS 12.3.5 DATABRIDGE ANALYSIS

12.4 SANOFI

12.4.1 COMPANY OVERVIEW 12.4.2 FINANCIAL ANALYSIS 12.4.3 PRODUCT MATRIX 12.4.4 RECENT DEVELOPMENTS 12.4.5 DATABRIDGE ANALYSIS

12.5 ELI LILLY AND COMPANY

12.5.1 COMPANY OVERVIEW 12.5.2 FINANCIAL ANALYSIS 12.5.3 PRODUCT MATRIX 12.5.4 RECENT DEVELOPMENTS 12.5.5 DATABRIDGE ANALYSIS

12.6 YPSOMED

12.6.1 COMPANY OVERVIEW 12.6.2 FINANCIAL ANALYSIS 12.6.3 PRODUCT MATRIX 12.6.4 RECENT DEVELOPMENTS 12.6.5 DATABRIDGE ANALYSIS

12.7 ANIMAS CORPORATION (JOHNSON AND JOHNSON)

12.7.1 COMPANY OVERVIEW 12.7.2 FINANCIAL ANALYSIS 12.7.3 PRODUCT MATRIX 12.7.4 RECENT DEVELOPMENTS 12.7.5 DATABRIDGE ANALYSIS

12.8 TANDEM DIABETES CARE, INC.

12.8.1 COMPANY OVERVIEW 12.8.2 FINANCIAL ANALYSIS 12.8.3 PRODUCT MATRIX 12.8.4 RECENT DEVELOPMENTS 12.8.5 DATABRIDGE ANALYSIS

12.10 INSULET CORPORATION

12.10.1 COMPANY OVERVIEW 12.10.2 FINANCIAL ANALYSIS 12.10.3 PRODUCT MATRIX 12.10.4 RECENT DEVELOPMENTS 12.10.5 DATABRIDGE ANALYSIS

12.10 BIOCON

12.10.1 COMPANY OVERVIEW 12.10.2 FINANCIAL ANALYSIS 12.10.3 PRODUCT MATRIX 12.10.4 RECENT DEVELOPMENTS 12.10.5 DATABRIDGE ANALYSIS

12.11 OWEN MUMFORD LTD.

12.11.1 COMPANY OVERVIEW 12.11.2 FINANCIAL ANALYSIS 12.11.3 PRODUCT MATRIX 12.11.4 RECENT DEVELOPMENTS 12.11.5 DATABRIDGE ANALYSIS

12.12 COPERNICUS

12.12.1 COMPANY OVERVIEW 12.12.2 FINANCIAL ANALYSIS 12.12.3 PRODUCT MATRIX 12.12.4 RECENT DEVELOPMENTS 12.12.5 DATABRIDGE ANALYSIS

12.13 F. HOFFMANN-LA ROCHE LTD

12.13.1 COMPANY OVERVIEW 12.13.2 FINANCIAL ANALYSIS 12.13.3 PRODUCT MATRIX 12.13.4 RECENT DEVELOPMENTS 12.13.5 DATABRIDGE ANALYSIS

12.14 ABBOTT

12.14.1 COMPANY OVERVIEW 12.14.2 FINANCIAL ANALYSIS 12.14.3 PRODUCT MATRIX 12.14.4 RECENT DEVELOPMENTS 12.14.5 DATABRIDGE ANALYSIS

12.15 B. BRAUN MELSUNGEN AG

12.15.1 COMPANY OVERVIEW 12.15.2 FINANCIAL ANALYSIS 12.15.3 PRODUCT MATRIX 12.15.4 RECENT DEVELOPMENTS 12.15.5 DATABRIDGE ANALYSIS

12.16 INJEXUK

12.16.1 COMPANY OVERVIEW 12.16.2 FINANCIAL ANALYSIS 12.16.3 PRODUCT MATRIX 12.16.4 RECENT DEVELOPMENTS 12.16.5 DATABRIDGE ANALYSIS

12.17 ANTARES PHARMA

12.17.1 COMPANY OVERVIEW 12.17.2 FINANCIAL ANALYSIS 12.17.3 PRODUCT MATRIX 12.17.4 RECENT DEVELOPMENTS 12.17.5 DATABRIDGE ANALYSIS

12.18 TERUMO MEDICAL CORPORATION

12.18.1 COMPANY OVERVIEW 12.18.2 FINANCIAL ANALYSIS 12.18.3 PRODUCT MATRIX 12.18.4 RECENT DEVELOPMENTS 12.18.5 DATABRIDGE ANALYSIS

12.19 ASTRAZENECA

12.19.1 COMPANY OVERVIEW 12.19.2 FINANCIAL ANALYSIS 12.19.3 PRODUCT MATRIX 12.19.4 RECENT DEVELOPMENTS 12.19.5 DATABRIDGE ANALYSIS

13 APPENDIX 14 ABOUT DATA BRIDGE MARKET RESEARCH

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART